UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 81

Sortiert nach

Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study

Journal of clinical oncology, 2010-07, Vol.28 (21), p.3491-3497

2010

Volltextzugriff (PDF)

Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies

Clinical cancer research, 2009-02, Vol.15 (4), p.1460-1465

2009

Volltextzugriff (PDF)

A Pilot Phase II Study of Valproic Acid for Treatment of Low‐Grade Neuroendocrine Carcinoma

The oncologist (Dayton, Ohio), 2011-06, Vol.16 (6), p.835-843

2011

Volltextzugriff (PDF)

Clinical Characteristics and Outcomes From an Institutional Series of Acinar Cell Carcinoma of the Pancreas and Related Tumors

Journal of clinical oncology, 2002-12, Vol.20 (24), p.4673-4678

2002

Volltextzugriff (PDF)

first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

Cancer chemotherapy and pharmacology, 2011-02, Vol.67 (2), p.447-454

2011

Volltextzugriff (PDF)

Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma

Neuro-oncology (Charlottesville, Va.), 2017-07, Vol.19 (7), p.965-975

2017

Volltextzugriff (PDF)

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

Neuro-oncology (Charlottesville, Va.), 2019-01, Vol.21 (1), p.106-114

2019

Volltextzugriff (PDF)

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

Cancer chemotherapy and pharmacology, 2017-12, Vol.80 (6), p.1209-1217

2017

Volltextzugriff (PDF)

Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study

Journal of neuro-oncology, 2017-01, Vol.131 (1), p.105-115

2017

Volltextzugriff (PDF)

Comparison of Biomarker Assays for EGFR : Implications for Precision Medicine in Patients with Glioblastoma

Clinical cancer research, 2019-06, Vol.25 (11), p.3259-3265

2019

Volltextzugriff (PDF)

A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806

The Journal of nuclear medicine (1978), 2021-06, Vol.62 (6), p.787

2021

Volltextzugriff (PDF)

Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma

Neuro-oncology (Charlottesville, Va.), 2018-05, Vol.20 (6), p.838-847

2018

Volltextzugriff (PDF)

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low‐Grade Neuroendocrine Tumors

The oncologist (Dayton, Ohio), 2016-07, Vol.21 (7), p.785-786g

2016

Volltextzugriff (PDF)

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2015-11, Vol.76 (5), p.1025-1032

2015

Volltextzugriff (PDF)

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer

Cancer, 2012-05, Vol.118 (9), p.2424-2430

2012

Volltextzugriff (PDF)

Molecular imaging in oncology drug development

Drug discovery today, 2017-01, Vol.22 (1), p.140-147

2017

Volltextzugriff (PDF)

Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins

Clinical advances in hematology & oncology, 2009-01, Vol.7 (1), p.54-64

2009

Volltextzugriff (PDF)

Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study

The lancet. Gastroenterology & hepatology, 2017-06, Vol.2 (6), p.418-426

2017

Volltextzugriff (PDF)

Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR

Cancer chemotherapy and pharmacology, 2017-05, Vol.79 (5), p.915-922

2017

Volltextzugriff (PDF)

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study

Cancer chemotherapy and pharmacology, 2015-11, Vol.76 (5), p.1041-1049

2015

Volltextzugriff (PDF)

Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors

Molecular cancer therapeutics, 2018-01, Vol.17 (1), p.215-221

2018

Volltextzugriff (PDF)

First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer

Cancer chemotherapy and pharmacology, 2012-03, Vol.69 (3), p.733-741

2012

Volltextzugriff (PDF)

A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors

Investigational new drugs, 2015-02, Vol.33 (1), p.169-176

2015

Volltextzugriff (PDF)

A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

Investigational new drugs, 2011-12, Vol.29 (6), p.1475-1481

2011

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(81)

Sprache

Englisch
(81)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(45)
Life Sciences & Biomedicine
(42)
Science & Technology
(42)
Oncology
(35)
Female
(33)
Male
(33)
Middle Aged
(32)
Aged
(31)
Adult
(24)
Neoplasms - Drug Therapy
(17)
Medicine
(16)
Medicine & Public Health
(16)
Pharmacology & Pharmacy
(16)
Pharmacology/toxicology
(15)
Aged, 80 And Over
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Biological And Medical Sciences
(13)
Maximum Tolerated Dose
(13)
Medical Sciences
(13)
Antineoplastic Agents - Therapeutic Use
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study

Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies

A Pilot Phase II Study of Valproic Acid for Treatment of Low‐Grade Neuroendocrine Carcinoma

Clinical Characteristics and Outcomes From an Institutional Series of Acinar Cell Carcinoma of the Pancreas and Related Tumors

first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study

Comparison of Biomarker Assays for EGFR : Implications for Precision Medicine in Patients with Glioblastoma

A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806

Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low‐Grade Neuroendocrine Tumors

Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer

Molecular imaging in oncology drug development

Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins

Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study

Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study

Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors

First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer

A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors

A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

Suchergebnisse filtern